| Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers A Fernández Montes, N Martínez Lago, M Covela Rúa, ... Cancer Medicine 8 (3), 882-889, 2019 | 42 | 2019 |
| Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer A Carmona-Bayonas, P Jimenez-Fonseca, M Garrido, A Custodio, ... Thrombosis and Haemostasis 119 (11), 1849-1859, 2019 | 32 | 2019 |
| Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry A Cotes Sanchís, J Gallego, R Hernandez, V Arrazubi, A Custodio, ... PLoS One 15 (7), e0235848, 2020 | 23 | 2020 |
| Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of … A Fernandez Montes, F Vazquez Rivera, N Martinez Lago, M Covela Rúa, ... Clinical and Translational Oncology 22, 351-359, 2020 | 17 | 2020 |
| FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX … AF Montes, NM Lago, J De la Cámara Gómez, MC Rúa, AC Castiñeiras, ... Annals of Oncology 30, iv23-iv24, 2019 | 16 | 2019 |
| Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib P Jiménez-Fonseca, MN Martín, A Carmona-Bayonas, A Calvo, ... Oncotarget 9 (97), 36894, 2018 | 15 | 2018 |
| Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data A Fernández Montes, A Carmona-Bayonas, P Jimenez-Fonseca, ... Scientific Reports 11 (1), 14321, 2021 | 13 | 2021 |
| Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study F Longo, M Jorge, R Yaya, AF Montes, NM Lago, E Brozos, J Aparicio, ... Future Oncology 17 (14), 1777-1791, 2021 | 11 | 2021 |
| Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry F Alvarez-Manceñido, P Jimenez-Fonseca, A Carmona-Bayonas, ... Gastric Cancer 24, 926-936, 2021 | 10 | 2021 |
| External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? P Jimenez-Fonseca, A Carmona-Bayonas, E Martínez de Castro, ... Gastric Cancer 24, 445-456, 2021 | 10 | 2021 |
| Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma K Conde‐Pérez, E Buetas, P Aja‐Macaya, E Martin‐De Arribas, ... Molecular Oncology 18 (5), 1143-1173, 2024 | 8 | 2024 |
| Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting N Martínez-Lago, TC Chucla, BA De Castro, RV Ponte, CR Rendo, ... Scientific Reports 12 (1), 14612, 2022 | 8 | 2022 |
| Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real … N Martínez-Lago, A Fernández-Montes, M Covela, EM Brozos, ... BMC cancer 21, 1-10, 2021 | 8 | 2021 |
| Dynamic perspective of the neutrophil-to-lymphocyte ratio in metastatic gastric cancer AC Castineiras, EG Martin, AF Montes, MC Campos, MC Rua, ... J BUON 26 (5), 2131-2140, 2021 | 8 | 2021 |
| Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population NM Lago, MV Villar, RV Ponte, IA Nallib, JJC Alvarez, JRA López, ... ecancermedicalscience 14, 2020 | 8 | 2020 |
| External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry P Jimenez-Fonseca, A Carmona-Bayonas, A Martinez-Torron, M Alsina, ... Therapeutic Advances in Medical Oncology 13, 17588359211019672, 2021 | 7 | 2021 |
| The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis K Conde‐Pérez, P Aja‐Macaya, E Buetas, N Trigo‐Tasende, ... Molecular Oncology 18 (5), 1093-1122, 2024 | 6 | 2024 |
| Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry JG Plazas, A Arias-Martinez, A Lecumberri, EM de Castro, A Custodio, ... ESMO open 7 (3), 100514, 2022 | 6 | 2022 |
| Impact of risk factors on the efficacy and complications of ultrasound-guided percutaneous liver biopsy of space-occupying lesions R Varela-Ponte, N Martínez-Lago, M Vieito-Villar, JM Carreira-Villamor Radiología (English Edition) 64 (6), 497-505, 2022 | 5 | 2022 |
| Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction N Martínez-Lago, M Vieito-Villar, Y Vidal-Insua, ME Padin-Iruegas, ... Clinical and Translational Oncology 17, 856-861, 2015 | 5 | 2015 |
